A detailed history of Franklin Resources Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 128,985 shares of TGTX stock, worth $4.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
128,985
Previous 124,229 3.83%
Holding current value
$4.02 Million
Previous $2.21 Million 36.47%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$17.21 - $25.28 $81,850 - $120,231
4,756 Added 3.83%
128,985 $3.02 Million
Q2 2024

Aug 14, 2024

BUY
$13.32 - $19.19 $96,063 - $138,398
7,212 Added 6.16%
124,229 $2.21 Million
Q1 2024

May 13, 2024

BUY
$13.02 - $21.3 $678,224 - $1.11 Million
52,091 Added 80.23%
117,017 $1.78 Million
Q4 2023

Feb 09, 2024

BUY
$6.68 - $18.81 $202,550 - $570,356
30,322 Added 87.63%
64,926 $1.11 Million
Q3 2023

Nov 13, 2023

SELL
$8.36 - $26.5 $299,371 - $948,965
-35,810 Reduced 50.86%
34,604 $289,000
Q2 2023

Aug 11, 2023

BUY
$15.48 - $35.0 $1.09 Million - $2.46 Million
70,414 New
70,414 $1.75 Million
Q4 2018

Feb 12, 2019

SELL
$3.44 - $5.76 $6.51 Million - $10.9 Million
-1,892,978 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$5.15 - $14.0 $2.02 Million - $5.48 Million
-391,499 Reduced 17.14%
1,892,978 $10.6 Million
Q2 2018

Aug 14, 2018

SELL
$12.5 - $15.0 $1.62 Million - $1.94 Million
-129,220 Reduced 5.35%
2,284,477 $30 Million
Q1 2018

May 10, 2018

SELL
$8.7 - $16.8 $380,346 - $734,462
-43,718 Reduced 1.78%
2,413,697 $34.3 Million
Q4 2017

Feb 14, 2018

BUY
$7.35 - $12.3 $642,375 - $1.07 Million
87,398 Added 3.69%
2,457,415 $20.2 Million
Q3 2017

Nov 13, 2017

BUY
$10.0 - $12.7 $23.7 Million - $30.1 Million
2,370,017
2,370,017 $28.1 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.53B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.